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Background: This study is aimed at evaluating the pharmacotherapy of obstructive airway diseases (OAD) in the
Montenegrin outpatient care (MOC) in 2010.
Methods: Data on the reimbursed drugs which were prescribed during the reference period were obtained from
the National Database that was established within the Health Insurance Fund of Montenegro in 2004. We have
applied the standard pharmacoepidemiologic methodology with the defined daily dose (DDD) along with the
Anatomical Therapeutic Chemical (ATC) classification of drugs. Clinical entities of OAD were classified according to
the International Classification of Diseases (ICD-Revision X).
Results: Prescribing and the subsequent use of drugs for OAD (ATC code R03) in 2010 was 18.18 DDD/
1000inhabitants/day, much lower than in some developed countries. Fenoterol/ipratropium and salmeterol/
fluticasone fixed combinations had the highest utilisation level, accounting for more than 50% of all OAD drugs.
About 90% of OAD drugs were prescribed for COPD and asthma.
Conclusions: Obtained results indicate that there are still large differences in OAD drug utilisation in MOC when
compared with developed countries, but also some improvement in pharmacological approach to the
pharmacotherapy of OAD in comparison to the earlier period.
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Obstructive airway disease (OAD) is a respiratory disease
category comprising several clinical entities. Although there
are significant clinical, pharmacological, epidemiological,
social and economic aspects typical of each of the entities,
asthma and chronic obstructive pulmonary disease (COPD)
are considered to have a particular impact on individuals,
their families, health care system and the society in general.
Asthma is a worldwide problem, with the estimate of 300
million of affected individuals and global prevalence ran-
ging from 1% to 18% of population across countries [1,2].
Medications for the asthma treatment can be classified as* Correspondence: duborijan@ac.me
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use, distribution, and reproduction in any medcontrollers or relievers. Controllers are medications taken
on a daily and long-term basis to keep asthma under clin-
ical control, mainly through their anti-inflammatory effect.
Relievers are medications used on an as needed basis which
act quickly to reverse bronchoconstriction and relieve its
symptoms. Inhaled glucocorticosteroids are the most effect-
ive controller medications currently available. Rapid acting
inhaled β2- agonists are the medications of choice for relief
of bronchoconstriction and for the pretreatment of exer-
cise-induced bronchoconstriction, in both in adults and
children of all ages. Long acting inhaled β2-agonists (LABA)
including formoterol and salmeterol, should not be used as
monotherapy in asthma as these medication do not appear
to influence the airway inflammation in asthma. They are
the most effective when combined with inhaled glucocorti-
costeroids, and this combination therapy is the preferredensee BioMed Central Ltd. This is an Open Access article distributed under the
icense (http://creativecommons.org/licenses/by/2.0), which permits unrestricted
ium, provided the original work is properly cited.
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oids fails to achieve control of asthma. According to the
Global Strategy for Asthma Management and Prevention,
the goal of asthma treatment is to achieve and maintain
clinical control [3].
COPD is the fourth largest cause of morbidity and
mortality in the developed world [4] and it doubles the
load on a healthcare system when it comes from elderly
persons when compared to the age- and gender-matched
controls [5]. Drugs treating COPD are exactly the same
as those for asthma, except that long-acting anticholin-
ergic drugs are more effective bronchodilators than
LABA [6-9]. Bronchodilator medications are central to
symptom management in COPD. Long- acting inhaled
bronchodilators are convenient and more effective at
producing maintained symptom relief than short-acting
bronchodilators. Combining bronchodilators of different
pharmacological classes may improve efficacy and de-
crease the risk of side effects compared to increasing the
dose of a single bronchodilator. The efficacy and side
effects of inhaled corticosteroids in asthma are
dependent on the dose and type of corticosteroid, but
whether this is also the case in COPD is unclear. Their
role in the management of stable COPD is limited to
specific indications. Long-term treatment with inhaled
corticosteroids added to long-acting bronchodilators is
recommended for patients at high risk of exacerbation
[10]. In terms of the overall goals, the pharmacotherapy
for COPD are directed at relieving symptoms, improving
health status, limiting lung function decline, improving
exercise tolerance, preventing deterioration, and de-
creasing mortality [3,11,12].
According to the Anatomical Therapeutic Chemical
(ATC) classification of drugs [13], the drugs which are
systemically or locally applied in the treatment of OAD
have the R03 code. It divides drugs into several groups
together with their combinations: selective and non-se-
lective adrenoceptor agonists (R03A, R03C), glucocorti-
coids (R03BA), anticholinergics (R03BB), antiallergic
agents (excluding corticosteroids) (R03BC), xanthines
(R03DA), leukotriene receptor agonists (R03DC) and
other newer drugs for OAD which cannot be classified
within the previous groups (R03DX).
Unlike many developed countries, where the surveil-
lance of drug utilisation has a rather long history and
plays an important role in improving pharmacotherapy
in many aspects, drug utilisation in Montenegrin out-
patient care (MOC) according to DDD (defined daily
dose)/ATC methodology was first investigated in 2000
[14]. Drugs for OAD were also subject to the above re-
search. The findings highlighted the fact that the extent
of prescribing these drugs was not optimal and needed
improvement: the overall utilisation was much lower
than in some developed countries, short-acting β2-agonists accounted for more than 50% and inhaled corti-
costeroids for only 13% of all prescribed drugs.
In order to evaluate the pharmacotherapy of OAD in
MOC, the objective of this study was to analyse the util-
isation of OAD drugs in 2010, comparing the findings
with the available data on drug utilisation in developed
countries, and analysing to what extent the OAD drugs
were prescribed by individual OAD diagnoses, according




This descriptive drug utilisation study comprises a sample
out of 100% of reimbursed OAD drugs (ATC code R03)
which were prescribed and subsequently used for the treat-
ment of OAD in MOC in 2010.
Data source
Introduction of the Information system named the Con-
trol of the Distribution and Use of Drugs into the Health
Insurance Fund of Montenegro (HIFM) in 2004 and the
implementation of electronic prescription in the Primary
Health Care (PHC) in 2008, as part of the Drug Policy
Reform Strategy, provided us with the 2010 data on the
reimbursed drugs prescribed for the OAD treatment in
the form of an electronic report. This report covered all
drugs with ATC code R03 which were issued on pre-
scription in state-owned pharmacies during the one-year
period, including the generic and trade name of a drug,
pharmaceutical form, the amount of pharmacologically
active substance, diagnosis for which a medication was
prescribed according to ICD-Revision X, the total num-
ber of DDD that were prescribed in 2010 for some diag-
nosis and costs in EUR. The number of DDD of a drug
contained in the electronic report was converted into
DDD/1000inhabitants/day (DTID), serving as a statis-
tical measure of the outpatient drug use. According
to the census from the beginning of 2011, the overall
population of Montenegro in 2010 was approximately
620 000 [15].
Reimbursement status of drugs for OAD in 2010
Drugs for OAD (ATC code R03) which were reimbursed
by HIFM in 2010 are shown in Table 1.
Under the current legislation, only reimbursed drugs
(so-called Positive List of Drugs) may be prescribed in
PHC and issued on prescription in state-owned pharma-
cies without compensation. Other drugs, which are not
on the Positive List, may be prescribed, but have to be
paid for in state-owned or private pharmacies. It was
found that about 30% of all the respiratory system drugs
(ATC code R) in 2000 were purchased in private phar-
macies [14]. Currently, there is no data available on the
Table 1 Drugs for OAD which were reimbursed by HIFM























Table 2 Prescribing of drugs for OAD (ATC code R03) in
MOC in 2010, in DDD/1000 inhabitants/day (DTID) and in









1. R03AK03 Fenoterol, ipratropium 6.11 33.6%
2. R03AK06 Salmeterol, fluticasone 3.41 18.8%
3. R03DA05 Aminophylline 2.43 13.4%
4. R03BA05 Fluticasone 1.98 10.9%
5. R03AC02 Salbutamol 1.89 10.4%
6. R03AC12 Salmeterol 1.45 8.0%
7. R03BA01 Beclomethasone 0.41 2.2%
8. R03DA04 Theophylline 0.35 1.9%
9. R03BA02 Budesonide 0.15 0.8%
10. R03BC01 Disodium cromoglycate 0.00 0.0%
R03 Total 18.18 100.0%
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current Positive List has been almost twofold; this prob-
ably results in a decrease in the proportion of purchased
drugs. Unfortunately, the application of the described
methodology implied that those drugs could not be sub-
ject to this study.
Utilization of drugs for OAD in MOC in comparison to
developed countries
Norway and Finland were chosen for the evaluation of the
obtained results against the accessible data from developed
countries for several reasons. As developed Scandinavian
economies with developed healthcare systems and the high-
est pharmacotherapeutic standards, these countries have a
long history of drug utilisation surveillance and the access-
ible data on the different aspects of drug use.
International Classification of Diseases (ICD), Revision X
The subject of this study was also based on the prescription
of OAD drugs for ICD J42-J46 codes, including a number
of clinical entities: unspecified chronic bronchitis-J42, em-
physema-J43, chronic obstructive pulmonary disease-J44,
asthma-J45, and status asthmaticus-J46. As already said
herein, the 2010 data on prescribed drugs by specific diag-
noses were collected from the electronic report.
Results
The prescribing and subsequent use of drugs for
OAD (ATC code R03) in MOC in 2010 is shown in
Table 2.
The overall use of drugs for OAD in MOC during the
reference period was 18.18 DDD/1000inhabitants/day.
The prescription of fixed combinations (fenoterol/
ipratropium and salmeterol/fluticasone) accounted forthe 52.4% share of all prescribed drugs. Aminophylline
was ranked as the third, with 2.43 DTID (13.4%). Other
drugs accounted for approximately one third of all pre-
scribed drugs.
Table 3 provides a comparative overview of the
utilization of drugs for OAD (ATC code R03) in MOC
and in the two Scandinavian countries in 2010.
As shown in Table 3, the total use of drugs for OAD in
Norway in 2010 was 3.5 times the Montenegrin rate (63.97
vs. 18.18 DTID), while this difference against Finland was
slightly smaller (58.34 vs. 18.18 DTID). The proportion of
fixed combinations amounted to about 50% in MOC. In
the observed Scandinavian countries, fixed combinations
accounted for approximately one third (31.6% in Norway
and 33.6% in Finland) of all the OAD drugs used. The most
commonly used drug in MOC (fenoterol/ipratropium)
made about one third of all prescribed drugs (6.11 DTID,
34%), but was used neither in Norway nor in Finland in
2010. On the other hand, drugs such as ipratropium brom-
ide, montelukast, tiotropium bromide and formoterol in
combination with corticosteroid were not prescribed in
MOC.
The aim of this paper was also to analyse the extent to
which OAD drugs (ATC code R03) were prescribed and
used in MOC for individual OAD diagnoses, according
to ICD-X Revision. The obtained results are provided in
Table IV.
As shown in Table 4, 91% of OAD drugs were prescribed
for COPD treatment (6.79 DTID, 49.7%) and asthma (5.64
DTID, 41.3%). Other clinical entities of OAD accounted for
about 9% of the overall use.
Given that OAD drugs were commonly used in 2010
to treat COPD and asthma, we also analysed their use
against each of these clinical entities separately. Results
are provided in Table 5 and Table 6.
Table 3 Utilization of drugs for OAD in MOC in comparison to Norway and Finland in 2010, in DDD/1000 inhabitants/day
(DTID) and in percent of total use
Ord. No MOC 2010 Norway 2010 Finland 2009
DTID (% of total use) DTID (% of total use) DTID (% of total use)
1. Fenoterol, ipratropium 6.11 (33.6 %) Salmeterol, corticosteroid 11.75 (18.4 %) Formoterol and other drugs for OAD 10.86 (18.6 %)
2. Salmeterol, fluticasone 3.41 (18.8 %) Salbutamol 11.32 (17.7 %) Salmeterol and other drugs for OAD 8.78 (15.0 %)
3. Aminophylline 2.43 (13.4 %) Ipratropium bromide 9.51 (14.9 %) Salbutamol 8.10 (13.9 %)
4. Fluticasone 1.98 (10.9 %) Formoterol, corticosteroid 8.43 (13.2 %) Fluticasone 5.49 (9.4 %)
5. Salbutamol 1.89 (10.4 %) Montelukast 4.70 (7.3 %) Budesonide 5.39 (9.2 %)
6. Salmeterol 1.45 (8.0 %) Tiotropium bromide 4.36 (6.8 %) Montelukast 5.16 (8.8 %)
7. Beclomethasone 0.41 (2.2 %) Fluticasone 3.11 (4.9 %) Tiotropium bromide 3.50 (6.0 %)
8. Theophylline 0.35 (1.9 %) Terbutaline 2.94 (4.6 %) Beclomethasone 3.27 (5.6 %)
9. Budesonide 0.15 (0.8 %) Budesonide 2.47 (3.9 %) Terbutaline 2.05 (3.5 %)
10. Othe 0.00 (0.0 %) Other 5.38 (8.4 %) Other 5.74 (9.8 %)
Total (R03) 18.18 (100.0 %) 63.97 (100.0 %) 58.34 (100.0 %)
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fenoterol and ipratropium was the most frequently used
COPD treatment drug (39%, 2.62 DTID). Salmeterol/fluti-
casone accounted for approximately 18% (1.20 DTID) of
the used, while fluticasone, aminophylline and salmeterol
were used at almost equal rates (11-12%).
The fixed combination of salmeterol and fluticasone
accounted for approximately one third of all drugs used
for the asthma treatment in MOC in 2010 (34%, 1.92
DTID). Fenoterol/ipratropium was used slightly less
(1.71 DTID, 30%) while other drugs (fluticasone, salbuta-
mol, aminophylline) accounted for approximately one
third of the overall use.
Discussion
Since there is no accurate data on the prevalence of OAD
in Montenegro, the obtained result of 18.18 DTID as a stat-
istical measure of drug use cannot be used to draw any final
conclusion on whether the use of OAD drugs, in terms of
quantity, was optimal or not. In theory, if each patient tookTable 4 Prescribing of OAD drugs (ATC code R03) by
diagnosis (ICD code J42-J46), in DDD/1000inhabitants/















J45 Asthma 5.64 41.3
J46 Status asthmaticus 0.04 0.3
Total (J42-J46) 13.66 100.0only one DDD of a single drug per day (which is often not
the case), than the results obtained could indicate the 1.8%
prevalence of OAD in the Montenegrin population.
The overall use of reimbursed OAD drugs in MOC
increased by over 100% in 2010 when compared to 2000
[14]. It is certain that the obtained result does not match
the increasing prevalence of OAD during the ten-year
period, but it probably appears as a result of a number of
influences, the individual contributions of which cannot be
assessed by this study. The Positive List of Drugs was
extended several times from 2000 to 2010, mostly due to a
favourable socioeconomic situation in the country. As an il-
lustration, gross domestic product (GDP) per capita in
Montenegro increased by more than 2.5 times in 2009
comparing to 2000 [16]. An extended Positive List implies
a wider choice for drug prescription by Montenegrin PHC
physicians. Furthermore, new recommendations on the
treatment of OAD at the global level, especially the intro-
duction of fixed combinations, have contributed addition-
ally to the obtained results.Table 5 OAD drug use (ATC code R03) for COPD
treatment (J44 according to ICD-X Revision) in 2010, in













3. R03BA05 Fluticasone 0.85 12.5
4. R03DA05 Aminophylline 0.81 11.9
5. R03AC12 Salmeterol 0.75 11.1
6. R03 Others 0.56 8.2
Total 6.79 100.0
Table 6 OAD drug use (ATC code R03) for the treatment
of asthma (J45 according to ICD-X Revision) in 2010, in













3. R03BA05 Fluticasone 0.73 12.9
4. R03AC02 Salbutamol 0.65 11.5
5. R03DA05 Aminophylline 0.35 6.2
6. R03 Others 0.28 5.1
Total 5.64 100.0
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positive shift from the earlier period [14]. In 2000, broncho-
dilators were dominant, led by salbutamol and aminophyl-
line, which could not be an indicator of rational
pharmacotherapy. Under-use of controllers, particularly
inhaled corticosteroids and prescription of non-asthma
medications, such as antibiotics, expectorants and antitus-
sives, were also observed in some developed countries dur-
ing the same period [17-21]. In 2010, the fixed
bronchodilator combination of fenoterol/ipratropium was
the most frequently prescribed in MOC (34%). It could be
subject to questioning because fenoterol was reported to
cause disturbances in cardiac function and even increase
the risk of death in patients with severe asthma, which is
why some developed countries have removed this drug
from the market [22-25]. A more frequent prescription of
controllers such as inhaled corticosteroids, LABA and their
combination in 2010 when compared to the earlier period,
indicates that there was some improvement in the OAD
pharmacological approaches. In addition, if apart from the
structure of used drugs the corticosteroid/bronchodilator
ratio is taken as a measure of quality of the OAD prescrib-
ing [26], a positive trend in the treatment of OAD within
MOC can be noticed.
In comparison to Norway and Finland, the total OAD
drug use in MOC is still of much smaller extent [27,28]. It
could partially be explained by different population morbid-
ity (Montenegro is a Mediterranean country) but also by
different financial opportunities which influence the level of
health care and legislation in relation to drugs. To illustrate
the above, the World Bank database classifies the observed
Scandinavian countries as ''high income'' ones, while Mon-
tenegro is an ''upper middle income'' country, with the
2010 GDP about 4.5 times lower than the one of Norway
[29]. Furthermore, the Positive List of Drugs in MOC con-
tained ten OAD drugs in 2010, while doctors in Norway
and Finland had a much wider choice when prescribing.
Still, it does not mean that a more rational prescribingpractice could not be established within the existing MOC
setting.
According to our results, the majority of OAD drugs
used in 2010 were also prescribed for the treatment of
COPD and asthma, as expected. The most commonly pre-
scribed fixed combination of short-acting bronchodilators
such as fenoterol and ipratropium could be partially justi-
fied when it comes to COPD, because bronchodilators are
considered the first-line therapy in the management of this
disease [11]. Nevertheless, it would be more appropriate if
this was replaced with long-acting drugs, such as tiotro-
pium bromide. However, since tiotropium bromide was not
covered by the Positive List of Drugs in 2010, the physicians
did not prescribe that drug. Or, to be more accurate, it
probably was being prescribed by PHC physicians, but
patients were buying it without reimbursement. The 18%
proportion of the salmeterol/fluticasone prescription for
the treatment of COPD can be considered as most likely
rational. Many studies have found this combination to re-
sult in an improvement in FEV1 and disease-specific quality
of life, and also to reduce the frequency of COPD deteriora-
tions and hospitalizations [30-32].
According to the British Thoracic Society Guidelines for
Asthma [33], the application of both inhaled corticosteroid
and LABA is not recommended prior to introducing the
third step (out of five) of asthma treatment. With fixed
combinations, particularly the questionable combination of
short-acting bronchodilators, accounting for about two
thirds of all drugs for asthma treatment in 2010, the
obtained results could indicate a possibly inadequate treat-
ment of patients with mild and/or moderate form of disease
which has been observed in some studies [34]. Additionally,
the pharmacoeconomic aspect of OAD drug prescription is
also very important [35,36] if we know that, according to
HIFM data [37], the fenoterol/ipratropium combination
accounted for approximately 22% of the overall costs for all
drugs which act on the respiratory system (ATC code R)
and about 2% of the total budget for drugs in 2009. To that
extent, doctors need to be further informed and educated.
Conclusions
In terms of both volume and type, there is still a much
lesser extent of the OAD drug prescription in MOC in
2010 than in developed countries like Norway and Finland
but it is remarkably larger when compared with the previ-
ous period. A larger share of controllers in the overall
number of prescriptions could partly indicate a better
pharmacotherapeutic approach to the OAD treatment. The
frequent prescription of fixed combinations for COPD and
asthma, especially of short-acting bronchodilators, requires
additional analysis and possible implementation of a new
regulation and/or educational activities among Monteneg-
rin PHC prescribers. Furthermore, the observed positive
trend should be encouraged in the future.
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